BackDr Reddy's Q2 net profit jumps over two-fold to ₹1,093 crore
The company had posted a profit of ₹503.80 crore for the year-ago period, Dr Reddy's saidRevenue in the second quarter stood at ₹4,800.9 crore as against ₹3,797.8 crore in the year-ago period, an increase of 26.41%
PremiumNEW DELHI : Dr Reddy's Laboratories on Friday reported over two-fold jump in consolidated net profit to ₹1,092.5 crore for the second quarter ended September 30, 2019.
The company had posted a profit of ₹503.80 crore for the year-ago period, Dr Reddy's said in a regulatory filing.
The net tax for the quarter has a benefit of ₹330 crore due to recognition of deferred tax assets of ₹520 crore, primarily related to the MAT credit, it said.
Revenue in the second quarter stood at ₹4,800.9 crore as against ₹3,797.8 crore in the year-ago period, an increase of 26.41 per cent, it added.
Company's Co-Chairman and MD GV Prasad said the performance across the businesses and strong cash generation during the quarter are pleasing.
"We are progressing well in execution of our strategy and in our transformation journey on quality and efficiency," he added.
Global generics segment revenues were at ₹3,280 crore, up 7 per cent from the same quarter last fiscal, primarily driven by Europe, emerging markets and India, the company said.
Revenues from North America were flat at ₹1,430 crore while that from Europe were at ₹280 crore. Revenues from India stood at ₹750 crore and emerging markets at ₹830 crore, it added.
Dr Reddy's said its pharmaceutical services and active ingredients revenue was at ₹710 crore, up 18 per cent from the corresponding period last fiscal.
Proprietary products segment clocked a revenue of ₹740 crore, including ₹720 crore towards licence fee for selling the US and select territory rights for two of neurology brands namely ZEMBRACE SYMTOUCH (sumatriptan injection) 3 mg and TOSYMRATM (sumatriptan nasal spray) 10 mg, to Upsher-Smith Laboratories, LLC, the company said.
Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!
This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.
